The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Coronary sinus reducer therapy for refractory angina: is it ready for prime time?

EuroIntervention 2021;17:530-531. DOI: 10.4244/EIJV17I7A94

1. National Heart and Lung Institute, Imperial College London, London, United Kingdom; 2. Imperial College Healthcare NHS Trust, London, United Kingdom
The contemporary treatment of angina is centred around improving coronary arterial flow and increasing perfusion of ischaemic myocardium. This is variably achieved with medication, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The coronary sinus reducer (CSR; Neovasc Inc., Richmond, BC, Canada) is the only therapy which attempts to improve angina by acting on the postcapillary myocardial circulation. Unlike PCI, which has an intuitive, well-described, extensively investigated mechanism, how the CSR affects angina is not well understood.

The CSR is an hourglass-shaped, balloon-mounted, wire-mesh device that reduces the coronary sinus lumen, after inflammation and fibrosis have caused ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Stratifying cardiovascular risk in patients with microvascular dysfunction: new insights from emerging physiology metrics